IDEAYA Biosciences, Inc. (IDYA) Balance Sheet
IDYA balance sheet, 2025
December 31, 2025 · U.S. dollars$1.11B assets = $86.4M liabilities + $1.02B equity
Both columns are drawn to the same scale: what IDYA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
IDYA financial health
Descriptive bands, not a rating. Fiscal 2025.
IDYA balance sheet trends, 2017–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $17.5M2017 | $1.11B2025 | +68.0%/yr | |
| Total liabilities | $33.2M2017 | $86.4M2025 | +12.7%/yr | |
| Shareholders’ equity | −$15.7M2017 | $1.02B2025 | — | |
| Cash & short-term investments | $13.2M2017 | $639.4M2025 | +62.5%/yr | |
| Total debt | $3.2M2017 | $27.9M2025 | +31.1%/yr | |
| Net cash (debt) | $9.9M2017 | $611.5M2025 | +$601.5M | |
| Working capital | $11.1M2017 | $607.9M2025 | +$596.8M | |
| Book value per share | $4.962019 | $11.562025 | +15.1%/yr | |
| Debt / equity | 0.072019 | 0.032025 | −0.04 | |
| Shares outstanding | 20.2M2019 | 88.5M2025 | +27.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IDYA assets
IDYA liabilities and equity
IDYA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
IDYA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $639.4M | $676.3M | $525.1M | $364.8M | $246.8M | $283.6M | $99.0M | $90.0M | $13.2M |
| Cash & equivalents | $112.8M | $84.4M | $157.0M | $68.6M | $92.0M | $72.0M | $34.1M | $20.5M | $6.0M |
| Short-term investments | $526.6M | $591.9M | $368.1M | $296.2M | $154.7M | $211.5M | $64.9M | $69.5M | $7.2M |
| Receivables | $6.0M | $3,000 | $18,000 | $211,000 | $1.1M | $1.9M | $0 | $0 | $0 |
| Inventory | $0 | $0 | $532.6M | −$8.3M | −$121.3M | $0 | $0 | $0 | $0 |
| Other current assets | $21.4M | $13.4M | $0 | $13.7M | $124.4M | $3.1M | $2.7M | $706,000 | $419,000 |
| Total current assets | $666.7M | $689.7M | $532.6M | $370.5M | $251.0M | $288.6M | $101.7M | $90.7M | $13.6M |
| Property, plant & equipment (net) | $31.3M | $27.7M | $8.4M | $9.0M | $8.7M | $9.5M | $9.7M | $5.2M | $3.7M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $410.3M | $405.8M | $107.5M | $8.3M | $121.3M | $0 | $1.5M | $0 | $0 |
| Other non-current assets | $1.0M | $805,000 | $782,000 | $205,000 | $397,000 | $188,000 | $122,000 | $722,000 | $160,000 |
| Total assets | $1.11B | $1.12B | $649.3M | $388.0M | $381.3M | $298.3M | $113.0M | $96.5M | $17.5M |
| Liabilities | |||||||||
| Accounts payable | $17.6M | $15.4M | $6.6M | $4.3M | $2.1M | $953,000 | $709,000 | $1.4M | $662,000 |
| Short-term debt | $339,000 | $298,000 | $1.7M | $1.9M | $1.7M | $1.5M | $1.1M | $0 | $0 |
| Deferred revenue | — | — | — | $8.6M | $29.0M | $27.6M | $5.0M | $299,000 | $297,000 |
| Total current liabilities | $58.8M | $46.1M | $27.1M | $31.7M | $45.2M | $38.6M | $6.9M | $5.4M | $2.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.2M |
| Lease obligations | $27.9M | $19.2M | $2.9M | $3.5M | $5.2M | $6.7M | $6.8M | $0 | $0 |
| Other long-term liabilities | $27.6M | $18.9M | $1.1M | $6.8M | $34.7M | $61.4M | $5.7M | $140.1M | $27.6M |
| Total liabilities | $86.4M | $64.9M | $28.2M | $38.5M | $79.8M | $100.0M | $12.6M | $145.5M | $33.2M |
| Shareholders' equity | |||||||||
| Common stock & paid-in capital | $9,000 | $9,000 | $7,000 | $5,000 | $4,000 | $3,000 | $2,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$736.5M | −$622.8M | −$348.4M | −$235.4M | −$176.7M | −$127.0M | −$92.5M | −$50.5M | −$16.2M |
| Treasury stock | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | $2.3M | $812,000 | $562,000 | −$2.9M | −$712,000 | $7,000 | $65,000 | −$31,000 | −$1,000 |
| Minority interest | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $1.02B | $1.06B | $621.1M | $349.5M | $301.5M | $198.3M | $100.4M | −$48.9M | −$15.7M |
| Key figures | |||||||||
| Total debt | $27.9M | $19.2M | $2.9M | $3.5M | $5.2M | $6.7M | $6.8M | $0 | $3.2M |
| Net cash (debt) | $611.5M | $657.1M | $522.2M | $361.3M | $241.6M | $276.9M | $92.2M | $90.0M | $9.9M |
| Working capital | $607.9M | $643.6M | $505.5M | $338.7M | $205.8M | $250.0M | $94.7M | $85.3M | $11.1M |
| Tangible book value | $1.02B | $1.06B | $621.1M | $349.5M | $301.5M | $198.3M | $100.4M | −$48.9M | −$15.7M |
| Book value per share | $11.56 | $12.97 | $10.80 | $8.43 | $8.55 | $8.02 | $4.96 | — | — |
| Shares outstanding | 88.5M | 81.7M | 57.5M | 41.4M | 35.3M | 24.7M | 20.2M | — | — |
| Current ratio | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
| Quick ratio | 10.97 | 14.68 | 19.38 | 11.51 | 5.49 | 7.39 | 14.26 | 16.62 | 5.41 |
| Debt / equity | 0.03 | 0.02 | 0.00 | 0.01 | 0.02 | 0.03 | 0.07 | — | — |
| Equity / assets | 92.2% | 94.2% | 95.7% | 90.1% | 79.1% | 66.5% | 88.8% | −50.7% | −90.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $829.0M | $671.2M | $639.4M | $786.9M | $669.7M | $692.5M | $676.3M | $920.0M | $701.7M | $698.8M | $525.1M | $468.8M |
| Cash & equivalents | $272.6M | $157.5M | $112.8M | $298.9M | $114.6M | $130.0M | $84.4M | $400.3M | $183.0M | $108.3M | $157.0M | $151.8M |
| Short-term investments | $556.4M | $513.7M | $526.6M | $488.0M | $555.1M | $562.5M | $591.9M | $519.7M | $518.6M | $590.4M | $368.1M | $316.9M |
| Receivables | $15.4M | $6.6M | $6.0M | $0 | $0 | $0 | $3,000 | $20,000 | $1,000 | $15,000 | $18,000 | $6.7M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 | $1 | $532.6M | −$42.4M |
| Other current assets | $19.7M | $18.3M | $21.4M | $15.8M | $15.9M | $15.4M | $13.4M | $12.2M | $11.5M | $10.6M | $0 | $49.1M |
| Total current assets | $864.0M | $696.1M | $666.7M | $802.7M | $685.6M | $707.9M | $689.7M | $932.2M | $713.2M | $709.4M | $532.6M | $482.2M |
| Property, plant & equipment (net) | $30.5M | $31.2M | $31.3M | $31.7M | $32.7M | $33.3M | $27.7M | $26.6M | $8.4M | $8.7M | $8.4M | $7.5M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $413.9M | $301.7M | $410.3M | $350.0M | $322.1M | $358.7M | $405.8M | $280.1M | $251.1M | $242.6M | $107.5M | $42.4M |
| Other non-current assets | $1.3M | $1.3M | $1.0M | $805,000 | $805,000 | $805,000 | $805,000 | $911,000 | $986,000 | $849,000 | $782,000 | $827,000 |
| Total assets | $1.31B | $1.03B | $1.11B | $1.19B | $1.04B | $1.10B | $1.12B | $1.24B | $973.7M | $961.5M | $649.3M | $532.9M |
| Liabilities | ||||||||||||
| Accounts payable | $30.5M | $20.7M | $17.6M | $18.4M | $17.3M | $17.6M | $15.4M | $12.6M | $15.9M | $6.3M | $6.6M | $5.2M |
| Short-term debt | $1.2M | $350,000 | $339,000 | $328,000 | $318,000 | $308,000 | $298,000 | — | $606,000 | $1.2M | $1.7M | $2.1M |
| Deferred revenue | — | — | — | $490,000 | — | — | — | — | — | — | — | $1.4M |
| Total current liabilities | $82.7M | $64.8M | $58.8M | $64.5M | $55.3M | $50.8M | $46.1M | $40.7M | $40.7M | $25.0M | $27.1M | $24.9M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $29.3M | $28.6M | $27.9M | $27.2M | $26.6M | $26.0M | $19.2M | $18.8M | $1.9M | $2.4M | $2.9M | $2.1M |
| Other long-term liabilities | $28.1M | $28.2M | $27.6M | $28.6M | $26.3M | $25.7M | $18.9M | $18.8M | $1.3M | $1.3M | $1.1M | $0 |
| Total liabilities | $110.8M | $93.1M | $86.4M | $93.1M | $81.6M | $76.5M | $64.9M | $59.5M | $42.0M | $26.2M | $28.2M | $24.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $10,000 | $9,000 | $9,000 | $9,000 | $9,000 | $9,000 | $9,000 | $9,000 | $8,000 | $7,000 | $7,000 | $6,000 |
| Retained earnings (deficit) | −$947.5M | −$835.1M | −$736.5M | −$653.3M | −$772.5M | −$695.0M | −$622.8M | −$492.5M | −$440.7M | −$387.9M | −$348.4M | −$314.4M |
| Accumulated other comprehensive income | −$1.7M | −$494,000 | $2.3M | $2.1M | $1.5M | $1.6M | $812,000 | $3.8M | −$1.4M | −$923,000 | $562,000 | −$750,000 |
| Total shareholders' equity | $1.20B | $937.3M | $1.02B | $1.09B | $959.7M | $1.02B | $1.06B | $1.18B | $931.7M | $935.3M | $621.1M | $508.0M |
| Key figures | ||||||||||||
| Total debt | $29.3M | $28.6M | $55.5M | $27.2M | $26.6M | $26.0M | $19.2M | $18.8M | $1.9M | $2.4M | $2.9M | $2.1M |
| Net cash (debt) | $799.6M | $642.6M | $583.9M | $759.6M | $643.1M | $666.5M | $657.1M | $901.2M | $699.8M | $696.4M | $522.2M | $466.7M |
| Working capital | $781.3M | $631.3M | $607.9M | $738.1M | $630.3M | $657.0M | $643.6M | $891.6M | $672.4M | $684.4M | $505.5M | $457.3M |
| Tangible book value | $1.20B | $937.3M | $1.02B | $1.09B | $959.7M | $1.02B | $1.06B | $1.18B | $931.7M | $935.3M | $621.1M | $508.0M |
| Book value per share | $13.02 | $10.57 | $11.55 | $12.18 | $10.85 | $11.59 | $12.97 | $13.70 | $11.95 | $12.45 | $9.52 | $8.47 |
| Shares outstanding | 92.1M | 88.7M | 88.6M | 89.7M | 88.5M | 88.4M | 81.7M | 86.2M | 78.0M | 75.1M | 65.2M | 60.0M |
| Current ratio | 10.45 | 10.74 | 11.34 | 12.44 | 12.39 | 13.92 | 14.97 | 22.93 | 17.50 | 28.42 | 19.65 | 19.37 |
| Quick ratio | 10.21 | 10.45 | 10.97 | 12.20 | 12.10 | 13.62 | 14.68 | 22.63 | 17.22 | 28.00 | 19.38 | 19.10 |
| Debt / equity | 0.02 | 0.03 | 0.05 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity / assets | 91.5% | 91.0% | 92.2% | 92.1% | 92.2% | 93.0% | 94.2% | 95.2% | 95.7% | 97.3% | 95.7% | 95.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 17, 2026); data from EODHD.
IDYA financial position
At the end of fiscal 2025 (December 31, 2025), IDEAYA Biosciences had total assets of $1.1 billion (down 1.3% from a year earlier), total liabilities of $86.4 million and shareholders' equity of $1.0 billion. It held $639.4 million in cash and short-term investments against $27.9 million of debt, a net cash position of $611.5 million. Its current ratio was 11.34. In the latest quarter (ended June 30, 2026) total assets were $1.3 billion and equity $1.2 billion.
Related: IDYA income statement, IDYA cash flow statement, IDYA key metrics. See the IDYA stock overview for the latest quote and news.
IDYA balance sheet FAQ
What are IDEAYA Biosciences's total assets?
IDEAYA Biosciences reported total assets of $1.1 billion at the end of fiscal 2025 (December 31, 2025), compared with $1.1 billion a year earlier.
How much debt does IDEAYA Biosciences have?
IDEAYA Biosciences had $27.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.03.
How much cash does IDEAYA Biosciences have?
IDEAYA Biosciences held $639.4 million in cash and short-term investments at the end of fiscal 2025; with $27.9 million of debt that is net cash of $611.5 million.
What is IDEAYA Biosciences's book value?
IDEAYA Biosciences's shareholders' equity (book value) was $1.0 billion at the end of fiscal 2025, or $11.56 per share.
What is IDEAYA Biosciences's current ratio?
IDEAYA Biosciences had current assets of $666.7 million and current liabilities of $58.8 million, a current ratio of 11.34 (it can cover its short-term obligations).